SQI Diagnostics Inc. (TSX-V: SQD), a life sciences and
diagnostics company that develops and commercializes proprietary
technologies and products for advanced microarray diagnostics (“SQI”)
today announced that they have entered into a method development
agreement with Isis Pharmaceuticals (Isis) to develop a multiplexed
assay that will utilize SQI’s Ig_PLEX™ multiplexing immunogenicity
technology.
“SQI is excited to develop a unique multiplex anti-drug antibody assay
for Isis as a first step to further the potential commercial
relationship between the two organizations,” said Andrew Morris, CEO of
SQI Diagnostics. “We believe that our multiplexing solutions and
services are highly complementary with Isis’ extensive portfolio of
drugs under development.”
The potential benefits to drug development companies using SQI’s Ig_PLEX
tests in their clinical studies include providing quantitative results
for multiple anti-drug antibody isotypes in a single test, utilizing
SQI’s automated systems to significantly improve the many benefits of
multiplexing during drug development’s immunogenicity testing phase, and
getting ahead of the emerging regulatory guidelines surrounding
immunogenicity testing worldwide.
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops
and commercializes proprietary technologies and products for advanced
microarray diagnostics. The Company’s proprietary microarray tests and
fully-automated systems are designed to simplify protein and antibody
testing workflow, increase throughput, reduce costs and provide
excellent data quality. For more information, please visit www.sqidiagnostics.com
FORWARD-LOOKING INFORMATION
This press release
contains certain forward-looking statements, including, without
limitation, statements containing the words “may”, “plan”, “will”,
“estimate”, “continue”, “anticipate”, “intend”, “expect”, “believe”, “in
the process”, “is subject to” and other similar expressions which
constitute “forward-looking information” within the meaning of
applicable securities laws. Forward-looking statements reflect the
Company's current expectation and assumptions, and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially from those anticipated. These forward-looking
statements involve risks and uncertainties including, but not limited
to, the ability of our patents to adequately protect our rights or
permit us to gain or keep any competitive advantage, and our ability to
market and sell our novel multiplexing technologies and detection
platforms. Such statements reflect the current views of the Company with
respect to future events and are subject to certain risks and
uncertainties and other risks detailed from time-to-time in the
Company’s ongoing filings with the securities regulatory authorities,
which filings can be found at www.sedar.com.
Actual results, events, and performance may differ materially. Readers
are cautioned not to place undue reliance on these forward-looking
statements. The Company undertakes no obligation to publicly update or
revise any forward-looking statements either as a result of new
information, future events or otherwise, except as required by
applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Copyright Business Wire 2013